Protego Bio

First-in-Class Therapies for Protein Misfolding Diseases

San Diego, United States · $181.0M raised

Headquarters
San Diego
Employees
1–10
Business Model
B2B
Total Funding
$181.0M
Last Round
$130.0M Series BDec 2025
Rounds
2

About

Protego Bio is a clinical-stage biotech headquartered in San Diego that develops first-in-class small molecule pharmacological chaperones to treat protein misfolding diseases such as AL amyloidosis. The company was co-founded by Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, who previously led the discovery of tafamidis, the first disease-modifying therapy for transthyretin amyloidosis. Protego Bio's lead candidate, PROT-001, is designed to stabilize misfolded light chain proteins and is advancing toward pivotal studies for AL amyloidosis, backed by $181 million raised across Series A and Series B financing.

Summary

Protego Bio is a Biotech company based in San Diego, United States. It has raised $181.0M in total across 2 rounds, most recently a $130.0M Series B round in Dec 2025. Investors include Lightspeed Venture Partners, MPM BioImpact and Novartis Venture Fund.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BDec 2025
$130.0M

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Protego Bio on Indexed.vc
<a href="https://indexed.vc/companies/protego-bio"><img src="https://indexed.vc/api/badge/company/protego-bio" alt="Protego Bio on Indexed.vc" width="260" height="76" /></a>